Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial

P. Merle; J.-F. Blanc; J.-M. Phelip; G. Pelletier; J.-P. Bronowicki; Y. Touchefeu; G. Pageaux; R. Gerolami; F. Habersetzer; E. Nguyen-Khac; A. Casadei-Gardini; I. Borbath; A. Tran; H. Wege; A.S. Saad; M. Colombo; A. Abergel; C. Richou; I. Waked; N.S. Yee; A. Molé; P. Attali; J. Le Boulicaut; B. Vasseur; D. Moussata; J.-D. Grangé; V. Ratziu; F. Khemissa-Akouz; H. Regnault; B. Dauvois; J.-P. Zarski; I. Ollivier-Hourmand; S. Manfredi; M. Debette-Gratien; A. Gangloff; T. Fontanges; A. Baron; M. Bouattour; J. Vincent; W. Sieghart; A. Maieron; M. Peeters; J. Delwaide; L. Lasser; T. Berg; M. Schultheiß; A. Zipprich; J. Trojan; U. Ehmer; G. Luppi; G. Luca; S. Tamberi; D. Amoroso; O. Alabiso; A. Buonadonna; P. Toniutto; E. Tamburini; A. Cubillo; A. Muñoz; C. Guillén; G. Sánchez; H. Manzano; V. Navarro; I. Ales; B. Massuti; M. Dank; G. Bodoky; Z. Kahan; Z. Horváth; N. Gabrail; H. Ozer; C. Galanopoulos; R. Hauke; M. Raj; H. Harputluoglu; A. Sevinc; E. Goker; A. Coker; S. Yalcin; M. Ali; O. Ata; I. Tugba; M. ElKassas; A. Abdel; I. Wakid; S. Shamaa; N. El; H. Kohail; J. Makarem; I. Chehade; F. Farhat; C. López; M. Marín

doi:10.1016/S2468-1253(19)30040-8

Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial

P. Merle, J.-F. Blanc, J.-M. Phelip, G. Pelletier, J.-P. Bronowicki, Y. Touchefeu, G. Pageaux, R. Gerolami, F. Habersetzer, E. Nguyen-Khac, A. Casadei-Gardini, I. Borbath, A. Tran, H. Wege, A.S. Saad, M. Colombo, A. Abergel, C. Richou, I. Waked, N.S. YeeA. Molé, P. Attali, J. Le Boulicaut, B. Vasseur, D. Moussata, J.-D. Grangé, V. Ratziu, F. Khemissa-Akouz, H. Regnault, B. Dauvois, J.-P. Zarski, I. Ollivier-Hourmand, S. Manfredi, M. Debette-Gratien, A. Gangloff, T. Fontanges, A. Baron, M. Bouattour, J. Vincent, W. Sieghart, A. Maieron, M. Peeters, J. Delwaide, L. Lasser, T. Berg, M. Schultheiß, A. Zipprich, J. Trojan, U. Ehmer, G. Luppi, G. Luca, S. Tamberi, D. Amoroso, O. Alabiso, A. Buonadonna, P. Toniutto, E. Tamburini, A. Cubillo, A. Muñoz, C. Guillén, G. Sánchez, H. Manzano, V. Navarro, I. Ales, B. Massuti, M. Dank, G. Bodoky, Z. Kahan, Z. Horváth, N. Gabrail, H. Ozer, C. Galanopoulos, R. Hauke, M. Raj, H. Harputluoglu, A. Sevinc, E. Goker, A. Coker, S. Yalcin, M. Ali, O. Ata, I. Tugba, M. ElKassas, A. Abdel, I. Wakid, S. Shamaa, N. El, H. Kohail, J. Makarem, I. Chehade, F. Farhat, C. López, M. Marín

Research output: Contribution to journal › Article › peer-review

Original language	Italian
Pages (from-to)	454-465
Number of pages	12
Journal	The Lancet Gastroenterology and Hepatology
Volume	4
Issue number	6
DOIs	https://doi.org/10.1016/S2468-1253(19)30040-8
Publication status	Published - 2019

Access to Document

10.1016/S2468-1253(19)30040-8

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85065066341&doi=10.1016%2fS2468-1253%2819%2930040-8&partnerID=40&md5=047d3d7e110a6e35b40a2e5ee585c378

Cite this

Merle, P., Blanc, J-F., Phelip, J-M., Pelletier, G., Bronowicki, J-P., Touchefeu, Y., Pageaux, G., Gerolami, R., Habersetzer, F., Nguyen-Khac, E., Casadei-Gardini, A., Borbath, I., Tran, A., Wege, H., Saad, A. S., Colombo, M., Abergel, A., Richou, C., Waked, I., ... Marín, M. (2019). Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial. The Lancet Gastroenterology and Hepatology, 4(6), 454-465. https://doi.org/10.1016/S2468-1253(19)30040-8

Merle, P, Blanc, J-F, Phelip, J-M, Pelletier, G, Bronowicki, J-P, Touchefeu, Y, Pageaux, G, Gerolami, R, Habersetzer, F, Nguyen-Khac, E, Casadei-Gardini, A, Borbath, I, Tran, A, Wege, H, Saad, AS, Colombo, M, Abergel, A, Richou, C, Waked, I, Yee, NS, Molé, A, Attali, P, Le Boulicaut, J, Vasseur, B, Moussata, D, Grangé, J-D, Ratziu, V, Khemissa-Akouz, F, Regnault, H, Dauvois, B, Zarski, J-P, Ollivier-Hourmand, I, Manfredi, S, Debette-Gratien, M, Gangloff, A, Fontanges, T, Baron, A, Bouattour, M, Vincent, J, Sieghart, W, Maieron, A, Peeters, M, Delwaide, J, Lasser, L, Berg, T, Schultheiß, M, Zipprich, A, Trojan, J, Ehmer, U, Luppi, G, Luca, G, Tamberi, S, Amoroso, D, Alabiso, O, Buonadonna, A, Toniutto, P, Tamburini, E, Cubillo, A, Muñoz, A, Guillén, C, Sánchez, G, Manzano, H, Navarro, V, Ales, I, Massuti, B, Dank, M, Bodoky, G, Kahan, Z, Horváth, Z, Gabrail, N, Ozer, H, Galanopoulos, C, Hauke, R, Raj, M, Harputluoglu, H, Sevinc, A, Goker, E, Coker, A, Yalcin, S, Ali, M, Ata, O, Tugba, I, ElKassas, M, Abdel, A, Wakid, I, Shamaa, S, El, N, Kohail, H, Makarem, J, Chehade, I, Farhat, F, López, C & Marín, M 2019, 'Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial', The Lancet Gastroenterology and Hepatology, vol. 4, no. 6, pp. 454-465. https://doi.org/10.1016/S2468-1253(19)30040-8

@article{cfa6c6b1d0bb4177bd5b854b212c28e2,

title = "Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial",

author = "P. Merle and J.-F. Blanc and J.-M. Phelip and G. Pelletier and J.-P. Bronowicki and Y. Touchefeu and G. Pageaux and R. Gerolami and F. Habersetzer and E. Nguyen-Khac and A. Casadei-Gardini and I. Borbath and A. Tran and H. Wege and A.S. Saad and M. Colombo and A. Abergel and C. Richou and I. Waked and N.S. Yee and A. Mol{\'e} and P. Attali and {Le Boulicaut}, J. and B. Vasseur and D. Moussata and J.-D. Grang{\'e} and V. Ratziu and F. Khemissa-Akouz and H. Regnault and B. Dauvois and J.-P. Zarski and I. Ollivier-Hourmand and S. Manfredi and M. Debette-Gratien and A. Gangloff and T. Fontanges and A. Baron and M. Bouattour and J. Vincent and W. Sieghart and A. Maieron and M. Peeters and J. Delwaide and L. Lasser and T. Berg and M. Schulthei{\ss} and A. Zipprich and J. Trojan and U. Ehmer and G. Luppi and G. Luca and S. Tamberi and D. Amoroso and O. Alabiso and A. Buonadonna and P. Toniutto and E. Tamburini and A. Cubillo and A. Mu{\~n}oz and C. Guill{\'e}n and G. S{\'a}nchez and H. Manzano and V. Navarro and I. Ales and B. Massuti and M. Dank and G. Bodoky and Z. Kahan and Z. Horv{\'a}th and N. Gabrail and H. Ozer and C. Galanopoulos and R. Hauke and M. Raj and H. Harputluoglu and A. Sevinc and E. Goker and A. Coker and S. Yalcin and M. Ali and O. Ata and I. Tugba and M. ElKassas and A. Abdel and I. Wakid and S. Shamaa and N. El and H. Kohail and J. Makarem and I. Chehade and F. Farhat and C. L{\'o}pez and M. Mar{\'i}n",

note = "Cited By :5 Export Date: 24 February 2020",

year = "2019",

doi = "10.1016/S2468-1253(19)30040-8",

language = "Italian",

volume = "4",

pages = "454--465",

journal = "The Lancet Gastroenterology and Hepatology",

issn = "2468-1253",

publisher = "Elsevier Ltd",

number = "6",

}

TY - JOUR

T1 - Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial

AU - Merle, P.

AU - Blanc, J.-F.

AU - Phelip, J.-M.

AU - Pelletier, G.

AU - Bronowicki, J.-P.

AU - Touchefeu, Y.

AU - Pageaux, G.

AU - Gerolami, R.

AU - Habersetzer, F.

AU - Nguyen-Khac, E.

AU - Casadei-Gardini, A.

AU - Borbath, I.

AU - Tran, A.

AU - Wege, H.

AU - Saad, A.S.

AU - Colombo, M.

AU - Abergel, A.

AU - Richou, C.

AU - Waked, I.

AU - Yee, N.S.

AU - Molé, A.

AU - Attali, P.

AU - Le Boulicaut, J.

AU - Vasseur, B.

AU - Moussata, D.

AU - Grangé, J.-D.

AU - Ratziu, V.

AU - Khemissa-Akouz, F.

AU - Regnault, H.

AU - Dauvois, B.

AU - Zarski, J.-P.

AU - Ollivier-Hourmand, I.

AU - Manfredi, S.

AU - Debette-Gratien, M.

AU - Gangloff, A.

AU - Fontanges, T.

AU - Baron, A.

AU - Bouattour, M.

AU - Vincent, J.

AU - Sieghart, W.

AU - Maieron, A.

AU - Peeters, M.

AU - Delwaide, J.

AU - Lasser, L.

AU - Berg, T.

AU - Schultheiß, M.

AU - Zipprich, A.

AU - Trojan, J.

AU - Ehmer, U.

AU - Luppi, G.

AU - Luca, G.

AU - Tamberi, S.

AU - Amoroso, D.

AU - Alabiso, O.

AU - Buonadonna, A.

AU - Toniutto, P.

AU - Tamburini, E.

AU - Cubillo, A.

AU - Muñoz, A.

AU - Guillén, C.

AU - Sánchez, G.

AU - Manzano, H.

AU - Navarro, V.

AU - Ales, I.

AU - Massuti, B.

AU - Dank, M.

AU - Bodoky, G.

AU - Kahan, Z.

AU - Horváth, Z.

AU - Gabrail, N.

AU - Ozer, H.

AU - Galanopoulos, C.

AU - Hauke, R.

AU - Raj, M.

AU - Harputluoglu, H.

AU - Sevinc, A.

AU - Goker, E.

AU - Coker, A.

AU - Yalcin, S.

AU - Ali, M.

AU - Ata, O.

AU - Tugba, I.

AU - ElKassas, M.

AU - Abdel, A.

AU - Wakid, I.

AU - Shamaa, S.

AU - El, N.

AU - Kohail, H.

AU - Makarem, J.

AU - Chehade, I.

AU - Farhat, F.

AU - López, C.

AU - Marín, M.

N1 - Cited By :5 Export Date: 24 February 2020

PY - 2019

Y1 - 2019

UR - https://www.sciencedirect.com/science/article/pii/S2468125319304248?via%3Dihub

U2 - 10.1016/S2468-1253(19)30040-8

DO - 10.1016/S2468-1253(19)30040-8

M3 - Articolo

SN - 2468-1253

VL - 4

SP - 454

EP - 465

JO - The Lancet Gastroenterology and Hepatology

JF - The Lancet Gastroenterology and Hepatology

IS - 6

ER -

Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial

Access to Document

Other files and links

Cite this